NCT05320406View on ClinicalTrials.gov

RElugolix VErsus LeUprolide Cardiac Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

January 30, 2025

Study Completion Date

December 30, 2025

Conditions
Biochemically Recurrent Prostate CarcinomaLocalized Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8
Interventions
RADIATION

Radiation therapy

Undergo radiation therapy

DRUG

Leuprolide

Given IM or SC

DRUG

Relugolix

Given PO

Trial Locations (4)

30308

Emory Proton Therapy Center, Atlanta

Emory University Hospital Midtown, Atlanta

30322

Emory University/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Prostate Cancer Foundation

OTHER

lead

Emory University

OTHER